Vandetanib
 | This article needs references that appear in reliable third-party publications. Primary sources or sources affiliated with the subject are generally not sufficient for a Wikipedia article. Please add more appropriate citations from reliable sources. (July 2009) |
| File:Vandetanib.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine | |
| Clinical data | |
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Biological half-life | 5 days (mean) |
| Identifiers | |
| CAS Number | 443913-73-3 |
| ATC code | none |
| PubChem | CID 3081361 |
| Chemical data | |
| Formula | C22H24BrFN4O2 |
| Molar mass | 475.354 g/mol[[Script error: No such module "String".]] |
Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR)[1]. It is a tyrosine kinase inhibitor.
Drug has a third target: inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer
Current status
Vandetanib is being developed by AstraZeneca. It is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. There have been some promising results from a phase III trial with docetaxel[2]. There have also been ambivalent results when used with pemetrexed[3] Another trial with docetaxel was recruiting in July 2009[4]. AstraZeneca withdrew regulatory submissions for Zactima in October 2009 after trials showed no benefit when the drug was administered alongside chemotherapy [5].
External links
- Cancerline.com: Vandetanib Information for Physicians
- AZ-Trials.com: AstraZeneca Clinical Trials Patient Recruiting (US)
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." /> |
This pharmacology-related article is a stub. You can help ssf by expanding it. |
- ↑ http://nci.nih.gov/Templates/drugdictionary.aspx?CdrID=269177
- ↑ http://www.sciencedaily.com/releases/2009/06/090601092237.htm "Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer" June 2009
- ↑ http://www.medpagetoday.com/MeetingCoverage/IASLC/15396 "IASLC: Vandetanib Fails to Improve NSCLC Outcomes with Pemetrexed" Aug 2009
- ↑ http://clinicaltrials.gov/ct2/show/NCT00687297
- ↑ http://www.guardian.co.uk/business/marketforceslive/2009/oct/28/astrazeneca-glaxosmithkline "AstraZeneca drops after it withdraws submissions for cancer drug"
- Pages with script errors
- Articles lacking reliable references from July 2009
- Articles with invalid date parameter in template
- All articles lacking reliable references
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Angiogenesis inhibitors
- Tyrosine kinase inhibitors
- Quinazolines
- Amines
- Organobromides
- Organofluorides
- Phenol ethers
- Piperidines
- 2Fix
- Pharmacology stubs
